Hoylu ökade återkommande intäkter med 39 procent för årets första kvartal och genererade hela 14 nya...
Immunicum specialises in the research and development of novel immunotherapies that target hard-to-t...
Hög aktivitet I takt med att den kliniska aktiviteten har tilltagit, tre kliniska studier som pågår ...
Redeye provides its comments on RLS’ Q1’22 report. With reimbursement in place in the Netherlands as...
Rapid growth due to demand for Studio’s services We raise sales estimates by 6.
Redeye states that Catella’s Q1 report proved a new higher baseline for profitability in Investment ...
Redeye sees a stable Q1 report from Speqta, with the disclosed numbers regarding Bidbrain being the ...
Redeye comments on the Q1-report from Starbreeze. Net sales were SEK 23.
Strong growth momentum continued into Q2 A transformative year with platform ramp-up from April Shar...
Expanding pipeline to apathy in neurological disorders Pirepemat Ph 2b in PD-falls started in Q1 No ...
Redeye states that the Q1 report from FlexQube was solid with record sales and order intake.
Raketech just released a soft Q1 report, and weak start to Q2.
Redeye states that the Q1 report was good, especially within Wireless.
Efterfrågan på Tessins tjänster är hög; intäkterna ökade med 37 procent under årets första kvartal j...
NoHo Partners' Q1 2022 results came in above Infront consensus expectations and it issued new guidan...
Redeye is encouraged to see that Inzile has received an order of 21 Pro4’s from Tier Mobility.
Physitrack stays strong despite external disruptions We add Champion Health to the figures Share tr...
Finepart publicerade idag den 10 maj 2022 sin delårsrapport för första kvartalet 2022.
Redeye comments on Immunicum’s Q1 2022 report, which we judge came without any major surprises.
Redeye comments on Amniotics' first quarter and updates its Base Case.
